From early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Endo Axiom (Endo) is a cutting-edge platform technology harnessing liver-specific nanoparticles, set to revolutionise diabetes treatment.
Established by esteemed academics from the University of Sydney and Sydney Local Health District, Endo Axiom secured a $2.2 million investment from Proto Axiom. As a proud member of the Proto Axiom family, Endo benefits from comprehensive commercial, technical, and financial support from Proto.
Dr. Nicholas Hunt, CEO of Endo, holds a Senior Lecturer position at Concord Clinical School and is a recipient of the MRFF Targeted Translation Research Accelerator (TTRA) and Sydney Research Accelerator (SOAR) awards. Joining him in this venture are co-founders Prof. David Le Couteur AO and Prof. Victoria Cogger, with Lawrence Gozlan presiding as Chairman.
